Koizumi Kiyoshi, Tamaki Nagara, Inoue Tomio, Kanaya Shinichi, Kuwabara Yasuo, Kousaka Tadako, Saiki Yasuhiko, Saga Tsuneo, Sone Teruki, Taki Junichi, Yamazaki Tetsurou
Department of Radiology, Hachioji Medical Center, Tokyo Medical University, 1163 Tate-machi, Hachioji, Tokyo 193-0998, Japan.
Ann Nucl Med. 2004 Feb;18(1):73-8. doi: 10.1007/BF02985618.
The Subcommittee on Survey of Nuclear Medicine Practice in Japan has performed a nationwide survey of nuclear medicine practice every five years since 1982 to provide detailed information on its current status.
Questionnaires were sent to every institution known to the Japan Radioisotope Association to provide nuclear medicine examinations. The questionnaires address the number and kind of nuclear medicine examinations performed as well as the kind and dose of the radiopharmaceuticals used during the month of June 2002. The annual number of total or specific examinations was then estimated.
Of the institutions sent questionnaires, 1,204 were for in vivo study, 124 were for in vitro study, and 36 were for positron emission tomography (PET) study. Out of these, 95.8% answered them. A total of 1,697 gamma cameras were installed in 1,160 facilities, of which 50% were dual-head cameras. The estimated total annual number of examinations expressed by the number of administered radiopharmaceuticals was 1.60 million, similar to that of the previous survey (1997). The frequency of study with single photon emission computed tomography (SPECT) increased to 40%, from 30% in the previous survey. The scintigraphy most frequently performed was bone (35%), followed by myocardium (24%) and brain perfusion (12%). All showed a continuous increase over the past 20 years. Tumor imaging, however, fell from third to fourth place. The most commonly used radiopharmaceutical for each scintigraphy was 99mTc-HMDP for bone, 201Tl-chloride for myocardium, 67Ga-citrate for tumor, and 123I-IMP for brain. A total of 29,376 PET studies were performed yearly. Among them, 18F-FDG rapidly increased 3.7-fold. 131I therapy for thyroid cancer and hyperthyroidism was conducted yearly in 1,647 and 3,347 patients, respectively. A total of 31.35 million in vitro radioassays were carried out yearly, the number of which has been decreasing continuously since 1992.
It was proved that the content of nuclear medicine practice in Japan has changed in the past five years. This report might be useful for understanding the current trends of nuclear medicine practice in Japan.
自1982年以来，日本核医学实践调查小组委员会每五年在全国范围内开展一次核医学实践调查，以提供其当前状况的详细信息。
向日本放射性同位素协会所知的每个提供核医学检查的机构发送调查问卷。问卷涉及2002年6月进行的核医学检查的数量和种类，以及所使用放射性药物的种类和剂量。然后估算每年的总检查次数或特定检查次数。
在发送调查问卷的机构中，1204家用于体内研究，124家用于体外研究，36家用于正电子发射断层扫描（PET）研究。其中，95.8%的机构进行了回复。1160个设施共安装了1697台伽马相机，其中50%为双头相机。以所施用放射性药物数量表示的每年检查总次数估计为160万次，与上一次调查（1997年）相似。单光子发射计算机断层扫描（SPECT）研究的频率从上次调查的30%增加到40%。最常进行的闪烁扫描是骨扫描（35%），其次是心肌扫描（24%）和脑灌注扫描（12%）。在过去20年中，所有这些检查都呈持续增加趋势。然而，肿瘤显像从第三位降至第四位。每种闪烁扫描最常用的放射性药物分别是用于骨扫描的99mTc-HMDP、用于心肌扫描的201Tl-氯化物、用于肿瘤扫描的67Ga-柠檬酸盐和用于脑扫描的123I-IMP。每年共进行29376次PET研究。其中，18F-FDG迅速增加了3.7倍。每年分别对1647例和3347例患者进行甲状腺癌和甲状腺功能亢进的131I治疗。每年共进行3135万次体外放射分析，自1992年以来，其数量一直在持续下降。
事实证明，日本核医学实践的内容在过去五年中发生了变化。本报告可能有助于了解日本核医学实践的当前趋势。
